link to page 2 

 
 INSIGHTi 
 
COVID-19 Vaccination: Selected U.S. Data 
Sources 
Updated October 6, 2022 
The sources below can help congressional staff track the U.S. Coronavirus Disease 2019 (COVID-19) 
vaccination campaign. 
This list reflects selected sources of frequently requested data. Methodologies differ between sources; 
readers can check websites’ notes and caveats for more information on how their data were collected and 
other important methodological concerns. For help interpreting data, congressional staff can contact CRS.  
In addition to the list of vaccination data sources, information on public attitudes toward vaccination 
includes CDC’s National Immunization Survey, COVIDVaxView, and State of Vaccine Confidence 
Insights Report, Kaiser Family Foundation, and a number of scholarly articles.  
Vaccines.gov maps vaccination sites. Vaccine Equity Planner (Ariadne Labs) helps identify areas that lack 
convenient vaccine access. 
About Vaccine Data 
State and local jurisdictions, federal agencies, and pharmacy partners determine the number and types of 
doses shipped (distributed) to vaccination sites. Providers then administer doses to patients and report 
administration data to jurisdictions and CDC. (See CDC’s COVID-19 Vaccination Data in the United 
States.)  
FDA has approved or authorized for emergency use several COVID-19 vaccines, summarized in Table 1. 
Congressional Research Service 
https://crsreports.congress.gov 
IN11595 
CRS INSIGHT 
Prepared for Members and  
 Committees of Congress 
 
  
 
Congressional Research Service 
2 
Table 1. COVID-19 Vaccines Approved or Authorized by FDA  
(as of October 6, 2022) 
 
Pfizer-BioNTech 
Moderna 
J&J/Janssen 
Novavax 
Primary 
Monovalent vaccine: 
Monovalent vaccine: 
One dose (ages 
Two doses (ages 12+) 
Series 
18+) 
 
Three doses (ages 6 
 
Two doses (ages 6 
months through 4 
months+) 
years) 
 
Three doses (certain 
 
Three doses (certain 
immunocompromised 
immunocompromised 
individuals aged 6 
individuals aged 5+) 
months+) 
 
Two doses (ages 5+) 
 
FDA 
Yes, monovalent vaccine 
Yes, monovalent vaccine 
Not approved 
Not approved 
Approval / 
approved under the name 
approved under the name 
Licensure 
Comirnaty as a two-dose 
Spikevax as a two-dose 
regimen for individuals 
regimen for individuals 
12+  
18+ 
Emergency 
Yes, monovalent vaccine 
Yes, monovalent vaccine 
Yes, authorized in 
Yes, authorized as a 
Use 
authorized as a 
authorized as a 
limited situations 
two-dose primary series 
Authorization  
due to risk of 
for ages 12+ 
 
three-dose primary 
 
two-dose primary 
(EUA) 
series for ages 6 
series for ages 6 
serious adverse 
months through 4 
months+ 
events: 
years 
 
third primary series 
 
single-dose 
primary series 
 
two-dose primary 
dose for certain 
series for ages 5+  
immunocompromised 
for ages 18+ 
individuals aged 6 
 
third dose for certain 
 
single booster 
immunocompromised 
months+ 
dose for ages 
individuals aged 5+ 
 
18+ 
 
single booster dose 
Yes, Bivalent vaccine 
for ages 5-11 
authorized as a single 
 
booster for ages 18+ 
Yes, Bivalent vaccine 
authorized as a single 
booster for ages 12+ 
Source: CRS based on FDA’s COVID-19 Vaccines. 
Notes: See FDA’s COVID-19 Vaccines for details. Monovalent vaccines contain a messenger RNA (mRNA) component from 
the original strain of SARS-CoV-2, the virus that causes COVID-19. Bivalent vaccines contain two mRNA components of 
SARS-CoV-2, one from the original strain and one from the Omicron BA.4/BA.5 variants. 
CDC and FDA maintain websites on recommended regimens and booster eligibility.  
Vaccination Data Sources 
CDC provides data on doses and people vaccinated, and aggregated data for certain federal entities 
(Bureau of Prisons, Department of Defense, Indian Health Service, and Veterans Health Administration; 
see “Data Table”). CDC also publishes vaccine effectiveness data. 
CDC (click map) compiles links to state dashboards, which may also track sub-state data.  
Non-CDC sources that provide analyses of CDC data and incorporate data from jurisdiction-specific 
sources:  
  Covid Act Now (CAN) 
  
 link to page 3  link to page 4  link to page 4  link to page 4  link to page 4  link to page 4  link to page 4  link to page 4  link to page 4  link to page 4  link to page 4  link to page 4  link to page 4 Congressional Research Service 
3 
  Health Equity Tracker (HET) 
  Kaiser Family Foundation (KFF) 
  Centers for Medicare & Medicaid Services (CMS) 
Table 2 links to websites containing vaccination statistics. 
Table 2. Links to Vaccination Data Sources 
Measure 
National 
State 
Local 
Doses distributed 
Number 
CDC  
CDC   
— 
Per capita 
CDC (download Data  CDC 
— 
Table) 
By vaccine type (J&J/Janssen, 
CDC  
CDC (download Data 
— 
Spikevax/Moderna, 
Table) 
Comirnaty/Pfizer-BioNTech, 
Novavax, and updated (bivalent) 
boosters)  
Doses administered 
Number 
CDC  
CDC  
 
 
Per capita 
CDC (download Data  CDC 
— 
Table) 
 
Per day (daily count and 7-day 
CDCa 
CDCa 
— 
average, trend) 
By vaccine type  
CDC  
CDC (download Data 
— 
Table) 
Booster doses administered in last 7 
CDCb 
CDCb 
— 
days 
People vaccinated 
People who received ≥1 dose 
CDC (also trend)a 
CDC (also trend)a 
CDC (county) 
(number) 
 
CDC (CBSA)b 
 
People who received ≥1 dose 
CDC 
CDC 
CDC (county) 
(percentage) 
CAN 
CANc 
CDC (CBSA)b 
CAN (county, metro 
area)c  
People fully vaccinatedd (number) 
CDC (also trend)a 
CDC (also trend)a 
CDC (county) 
 
 
CDC (CBSA)b 
People fully vaccinatedd (percentage) 
CDC  
CDC  
CDC (county, also case 
 
CANc 
rates and testing positivity 
map) 
  
  
CDC (CBSA)b 
  
CAN (county, metro 
area)c 
  
 link to page 4  link to page 4  link to page 4  link to page 4 Congressional Research Service 
4 
Measure 
National 
State 
Local 
People with booster doses  
CDCError! 
CDC (download Data 
CDC (county) 
Reference source 
Table)Error! Reference 
CDC (CBSA)b 
not found. (also 
source not found. (also 
trend)  
trend)  
CAN (county, metro 
area)c 
 
CANc 
Demographics 
CDC (race/ethnicity, 
CDC (sex, age, trends; also 
CDC (age, county and 
sex, age; also trends) 
maps) 
CBSA)b 
CDC (aged 65+) 
CDC (aged 65+) 
CDC (aged 65+, county) 
CDC (trends by age, 
CDCb (age) 
CDC (social vulnerability, 
alongside cases) 
CDC (urban/rural, trend) 
urban/rural, county) 
CDCb (people 
CDCb (people initiating 
CDC (people initiating 
initiating vaccination 
vaccination or receiving 
vaccination or receiving 
or receiving booster 
booster in last 7 days, by 
booster in last 7 days, by 
in last 7 days, by age) 
age) 
age, county and CBSA)b 
CDC (disability status  HET (race/ethnicity) 
 
and age, 
race/ethnicity) 
KFF (race/ethnicity) 
CDC (pregnant 
people by 
race/ethnicity, trend) 
CDC (urban/rural, 
trend) 
HET (race/ethnicity) 
KFF (race/ethnicity) 
Nursing homes 
Resident/staff vaccination rates 
CDC (trend) 
CDC (trend) 
CMS (facility-level data in 
CMS 
CMS 
“Search for a nursing 
home”) 
Medicare.gov (facility-level 
data) 
Source: CRS based on sources as of October 6, 2022. 
Notes:  
a.  See also 7-day average trend alongside cases or deaths, see “View (right axis).”  
b.  See spreadsheets under “Show More”: “Attachments.” Metropolitan and Micropolitan Statistical Areas are collectively 
known as Core-Based Statistical Areas (CBSAs). 
c.  Search state, city, or county, then scroll to “% Vaccinated” for trend. 
d.   “Fully vaccinated” people have received the second dose of a two-dose vaccine or one dose of a single-shot vaccine 
(CDC). 
e.  Includes number, percentage, vaccine type.  
  
Congressional Research Service 
5 
Author Information 
 
Ada S. Cornell 
  Angela Napili 
Senior Research Librarian 
Senior Research Librarian 
 
 
 
 
 
Disclaimer 
This document was prepared by the Congressional Research Service (CRS). CRS serves as nonpartisan shared staff 
to congressional committees and Members of Congress. It operates solely at the behest of and under the direction of 
Congress. Information in a CRS Report should not be relied upon for purposes other than public understanding of 
information that has been provided by CRS to Members of Congress in connection with CRS’s institutional role. 
CRS Reports, as a work of the United States Government, are not subject to copyright protection in the United 
States. Any CRS Report may be reproduced and distributed in its entirety without permission from CRS. However, 
as a CRS Report may include copyrighted images or material from a third party, you may need to obtain the 
permission of the copyright holder if you wish to copy or otherwise use copyrighted material. 
 
IN11595 · VERSION 21 · UPDATED